Global NMDA specialist

Working together for therapeutic options for managing clientswith a major depressive disorder (MDD),It is estimated that up to 18% of patients diagnosed with a major depressive disorder(MDD) do not respond to conventional treatments and medicationsand so these areclassified as treatment resistant.Our knowledge and data consultancyhas shown toreduce significant health, social, and economic burdens amongst the field of Psychiatry.However, at this timethere are was nopublishedavailable data or general guidelines on optimal dosage, dosage frequency, or intervaldosagesforthe administration of N-methyl-d-aspartatereceptor antagonistsother than that provided byanesthetic useinEmergency Room patients and induction.Global has paved the wayto sustain TRD and MDDremission together with healthcare groups and keyworkers. We aim to work with others who specialise in this field andwillassist or freelyofferour guidanceto those wishing toachieve thesustained remission of patients withMDD and TRD.